{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreiaq4arru6uihqylknu4jvdqxtrj62khuqgxrwki6pwsnyan7ks6ga",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3mmu4fqcsw2y2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreiegjj2nc5htmsga5zhgui6o3ckibqpzwa74gzfre67ifxp7fq6e6i"
    },
    "mimeType": "image/jpeg",
    "size": 103431
  },
  "path": "/news/2026-05-tirzepatide-superior-conventional-early-diabetes.html",
  "publishedAt": "2026-05-27T14:00:07.000Z",
  "site": "https://medicalxpress.com",
  "textContent": "Tirzepatide is superior to intensified conventional care (ICC) for adults with early type 2 diabetes (T2D) uncontrolled with metformin, according to a study published online May 26 in the Annals of Internal Medicine.",
  "title": "Tirzepatide superior to intensified conventional care for early type 2 diabetes"
}